Mortality in bronchiectasis: a long-term study assessing the factors influencing survival
- PMID: 19357155
- DOI: 10.1183/09031936.00003709
Mortality in bronchiectasis: a long-term study assessing the factors influencing survival
Abstract
There is little literature about the mortality associated with bronchiectasis. The aim of the present study was to investigate factors affecting mortality in patients with bronchiectasis. In total, 91 patients were examined for aetiology, pulmonary function tests, high-resolution computed tomography, sputum microbiology and quality of life scores and were then followed over 13 yrs. Overall, 29.7% of the patients died. On multivariate analysis, age, St George's Respiratory Questionnaire activity score, Pseudomonas aeruginosa infection, total lung capacity (TLC), residual volume/TLC and the transfer factor coefficient were all independently associated with mortality. In patients with moderate to severe bronchiectasis, mortality is associated with a degree of restrictive and obstructive disease, poor gas transfer and chronic pseudomonas infection. These features should guide future research into disease progression, and identify those patients needing intensive treatment.
Similar articles
-
Antibiotic-resistant Pseudomonas aeruginosa infection in patients with bronchiectasis: prevalence, risk factors and prognostic implications.Int J Chron Obstruct Pulmon Dis. 2018 Jan 9;13:237-246. doi: 10.2147/COPD.S150250. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 29386892 Free PMC article.
-
The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis.Eur Respir J. 2006 Nov;28(5):974-9. doi: 10.1183/09031936.06.00074605. Epub 2006 Aug 9. Eur Respir J. 2006. PMID: 16899482
-
Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis.Respir Med. 2014 Feb;108(2):287-96. doi: 10.1016/j.rmed.2013.12.015. Epub 2014 Jan 8. Respir Med. 2014. PMID: 24445062
-
A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis.Ann Am Thorac Soc. 2015 Nov;12(11):1602-11. doi: 10.1513/AnnalsATS.201506-333OC. Ann Am Thorac Soc. 2015. PMID: 26356317 Review.
-
[Pseudomonas aeruginosa infections in chronic obstructive pulmonary disease : Role of long-term antibiotic treatment].Internist (Berl). 2017 Nov;58(11):1142-1149. doi: 10.1007/s00108-017-0332-y. Internist (Berl). 2017. PMID: 28983645 Review. German.
Cited by
-
Factors influencing survival and mortality among adult Aboriginal Australians with bronchiectasis-A 10-year retrospective study.Front Med (Lausanne). 2024 May 7;11:1366037. doi: 10.3389/fmed.2024.1366037. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38774399 Free PMC article.
-
Impact of Respiratory Bacterial Findings on Patients with Chronic Pulmonary Aspergillosis.Int J Microbiol. 2024 Apr 30;2024:1329884. doi: 10.1155/2024/1329884. eCollection 2024. Int J Microbiol. 2024. PMID: 38716459 Free PMC article.
-
Hospital admission rates and related outcomes among adult Aboriginal australians with bronchiectasis - a ten-year retrospective cohort study.BMC Pulm Med. 2024 Mar 6;24(1):118. doi: 10.1186/s12890-024-02909-x. BMC Pulm Med. 2024. PMID: 38448862 Free PMC article.
-
Characterisation of airway disease associated with Sjögren disease.RMD Open. 2024 Feb 29;10(1):e003866. doi: 10.1136/rmdopen-2023-003866. RMD Open. 2024. PMID: 38428976 Free PMC article.
-
Clinical outcomes of long-term inhaled combination therapies in patients with bronchiectasis and airflow obstruction.BMC Pulm Med. 2024 Jan 23;24(1):49. doi: 10.1186/s12890-024-02867-4. BMC Pulm Med. 2024. PMID: 38263115 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
